Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency
Links shared publicly online about this topic.
- 1,378total visits
Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency
Octapharma AG today announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results from additional upcoming studies, will support its regulatory filing in Europe and the US.
View full resource at news-medical.net
Tags: Immune, Immune Deficiency
Most Recently Shared on February 16, 2010 at 8:50 am By:
Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency: Octaph... http://bit.ly/a1L0sJ
Advertisement
